Enliven Therapeutics Q3 EPS $(0.51) Misses $(0.47) Estimate
Portfolio Pulse from Benzinga Newsdesk
Enliven Therapeutics reported Q3 losses of $(0.51) per share, missing the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 29.17 percent increase over losses of $(0.72) per share from the same period last year.
November 09, 2023 | 10:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Enliven Therapeutics' Q3 earnings per share of $(0.51) missed the consensus estimate by 8.51%. However, this is a 29.17% improvement over last year's losses.
Enliven Therapeutics reported a larger loss than expected for Q3, which could negatively impact investor sentiment and potentially lead to a short-term drop in the stock price. However, the year-over-year improvement in losses might mitigate this impact to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100